Dyax Corp. Q4 Loss Narrows - Quick Facts

(RTTNews) - Dyax Corp. (DYAX) said that its fourth-quarter of net loss attributable to common stockholders narrowed to $1.964 million or $0.02 per share from the prior year's $4.834 million or $0.05 per share.

Total revenues for the fourth quarter were $16.9 million, as compared to $16.0 million for the comparable quarter in 2012. These include KALBITOR net sales of $12.6 million and $11.8 million for the fourth quarter of 2013 and 2012, respectively.

Analysts polled by Thomson Reuters expected the company to report a loss of $0.04 per share and revenues of $15.84 million for the quarter. Analysts' estimates typically exclude special items.

For 2014, the company projects Top-line total revenue to be in the range of $53-59 million, including KALBITOR net sales of $44-49 million. Due to the significant variability in the rate at which HAE patients treat their acute attacks, the Company relies on an annualized treatment rate for net sales guidance. Total top-line revenue excludes potential royalties which would be earned from sales of LFRP product candidates that may receive marketing approval in 2014.

Operating costs and expenses (cost of product sales, research and development expenses, and selling, general and administrative costs) are to be in the range of $72 million - $75 million for 2014.